BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 12.09.2006

Draft Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Drug Interaction Studies--Study Design, Data Analysis, and Implications for Dosing and Labeling." This document is intended to provide recommendations to sponsors of new drug applications (NDAs), and biologic license applications (BLAs) for therapeutic biologics (drugs) on carrying out in vitro or in vivo drug-drug interaction studies. The draft guidance reflects the current view that the metabolism and transport of a new drug should be defined during drug development and that its interactions with other drugs should be explored as part of an adequate assessment of the safety and effectiveness of the drug.

Source: Federal Register — Food and Drug AdministrationOpen original release →